Orum Therapeutics Provides Program Update and Announces Drug Candidate Nomination
BOSTON, USA & DAEJEON, South Korea, April 28, 2025 – Orum Therapeutics, Inc. (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced a strategic update to its pipeline. Orum has discontinued further clinical development of ORM-5029, a HER2-targeted GSPT1 degrader-antibody conjugate (DAC). This decision follows an internal assessment of the program’s clinical progress and incorporates information previously disclosed. Concurrently, Orum announced the nomination of a new drug candidate, ORM-1153, in development for the treatment of hematologic malignancies.
ORM-1153 is a novel DAC engineered using Orum’s proprietary Dual-Precision Targeted Protein Degradation (TPD²®) approach, which combines the catalytic protein degradation mechanism of TPDs with the tumor-targeting capabilities of therapeutic antibodies. The candidate targets GSPT1, a translation termination factor highly relevant in hematologic malignancies, and an undisclosed tumor-associated antigen to enhance selectivity and broaden the therapeutic window.
In preclinical studies, ORM-1153 demonstrated potent anti-tumor activity and a favorable safety profile, including in non-human primate models. ORM-1153 demonstrated picomolar potency in target-expressing cell lines and showed greater potency than existing small molecule GSPT1 degraders. In vivo, a single dose of ORM-1153 led to strong anti-tumor activity in relevant xenograft models. Orum plans to advance the program into IND-enabling studies and anticipates presenting additional data at a scientific conference later this year.
“After careful review of available clinical and preclinical data, we have concluded clinical development of ORM-5029,” said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum Therapeutics. “This decision reflects our continued commitment to patient safety and our strategic focus on advancing the next generation of degrader-antibody conjugates with a clearly defined risk-benefit profile. We look forward to advancing next-generation programs emerging from our proprietary platform, like ORM-1153.”
Dr. Lee continued, “ORM-1153 leverages learnings from all our programs and clinical experience to build potent, selective, and tumor-targeted protein degrader therapeutics that address serious unmet needs in oncology. We remain confident in the promise of our Dual-Precision Targeted Protein Degradation GSPT1 platform and are excited to progress this new candidate toward the clinic.”
About Orum’s TPD²® Approach
Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²®) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.
About Orum Therapeutics
Orum Therapeutics is a public biotech company pioneering the development of cell-specific, targeted protein degraders (TPD²®) with the precision of antibody targeting to improve cancer treatment for more patients. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum's novel targeted protein degrader payloads are designed to selectively degrade key intracellular proteins, offering a highly targeted approach to treating difficult-to-treat diseases. Orum is located in Daejeon, South Korea, and Lexington, MA, US. For more info, visit www.orumrx.com.
Orum Therapeutics Forward-Looking Statements
This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (“Orum”). Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the potential selectivity, therapeutic window, therapeutic benefits, and indications for ORM-1153; the potential for preclinical study results to indicate positive results in IND-enabling studies and any clinic trial; the potential for commencement of IND-enabling studies, the filing and approval of any IND application, and initiation of clinical trials; the presentation of additional ORM-1153 data during 2025; the promise of Orum’s GSPT1 platform; and the development of new payload platforms and programs and the expansion of Orum’s pipeline are forward-looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertainty of success in research and development activities; the uncertainty in approval of any IND that might be filed; competition from alternative therapies; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, and future fundraising. The forward-looking statements in this presentation speak only as of the date of this release, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release.
Contacts
Corporate: Kayla (Gyebang) Mo, Director, IR/PR, Orum Therapeutics, Inc., media@orumrx.com
Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., jessica@litldog.com
Orum Therapeutics Appoints Dr. Sang Hyun Lee as Vice President, Research Site Head, Korea, to Accelerate Innovation in Novel Degrader-Antibody Conjugates
BOSTON, USA & DAEJEON, South Korea, April 21, 2025 – Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a clinical-stage biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Sang Hyun (Shawn) Lee, Ph.D., as Vice President, Research Site Head, Korea. Dr. Lee brings over two decades of scientific leadership in cancer biology and drug discovery, including extensive experience in the discovery and development of protein degrader technologies. In this role, he will serve as a key bridge between Orum’s research teams in Korea and the U.S. to accelerate progress on the company’s Dual-Precision Targeted Protein Degradation (TPD²®) approach.
“This strategic appointment reflects Orum’s ongoing commitment to building global leadership in TPD-based therapeutics,” said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum Therapeutics. “Dr. Lee’s deep expertise in PROTACs, DACs, and TPD biology, combined with his leadership in bringing multiple novel molecules from discovery into the clinic, will be instrumental as we continue to develop next-generation degrader-antibody conjugate platforms and expand our pipeline.”
“I am excited to join Orum at this important time,” said Dr. Lee. “Orum is at the forefront of integrating antibody targeting with protein degrader technology to overcome limitations of traditional therapies. I look forward to working with the team to expand the potential of TPD payloads and help bring transformative therapies to patients.”
Previously, Dr. Lee held senior research leadership roles at Prelude Therapeutics and Arvinas, where he helped advance targeted protein degrader programs. He also held discovery leadership positions at Incyte Corporation and began his research career at Dana-Farber Cancer Institute and Harvard Medical School. Dr. Lee holds a Ph.D. in molecular and cell biology from the University of Texas at Dallas and completed postdoctoral research at Dana-Farber Cancer Institute. He has co-authored more than 20 peer-reviewed publications and led or co-led multiple successful Investigational New Drug (IND) submissions to the U.S. FDA.
About Orum’s TPD²® Approach
Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²®) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.
About Orum Therapeutics
Orum Therapeutics is a clinical-stage biotech pioneering the development of cell-specific, targeted protein degraders (TPD²®) with the precision of antibody targeting to improve cancer treatment for more patients. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum's novel targeted protein degrader payloads are designed to selectively degrade key intracellular proteins, offering a highly targeted approach to treating difficult-to-treat diseases. Orum is located in Lexington, MA, US, and Daejeon, South Korea. For more info, visit www.orumrx.com.
Orum Therapeutics Forward-Looking Statements
This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (“Orum”). Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the pace of progress in developing Orum’s technologies; the development of new payload platforms and the expansion of Orum’s pipeline; the potential for filing of IND applications and their approval; the potential initiation of clinical trials; and potential benefits to patients are forward-looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertainty of success in research and development activities; competition from alternative therapies; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, and future fundraising. The forward-looking statements in this presentation speak only as of the date of this release, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release.
Contacts
Corporate: Kayla (Gyebang) Mo, Director, IR/PR, Orum Therapeutics, media@orumrx.com
Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., jessica@litldog.com
Orum Therapeutics Announces Pricing of Initial Public Offering
BOSTON, USA & DAEJEON, South Korea, February 3, 2025 – Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a clinical-stage biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the pricing of its initial public offering of 2,500,000 shares of common stock at a public offering price of KRW 20,000 per share. All of the shares are being offered by Orum Therapeutics. The shares are expected to begin trading on the Korean Securities Dealers Automated Quotations (KOSDAQ) on February 14, 2025, under the stock code KRX: 475830. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Orum, are expected to be approximately KRW 50 billion.
The offering is expected to close on February 5, 2025, subject to the satisfaction of customary closing conditions.
Korea Investment Securities acted as underwriter for the offering.
A registration statement relating to the offering has been filed with the Financial Supervisory Service and was declared effective on January 16, 2025. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering, when available, may be obtained for free by visiting DART on the Financial Supervisory Service website at https://englishdart.fss.or.kr/. Alternatively, copies of the final prospectus, when available, may be obtained from Korea Investment Securities, Attention: https://securities.koreainvestment.com, by telephone at +82-2-3276-5783, +82-2-3276-5783-4528, or by email at KIS_COMM@koreainvestment.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Korean Securities and Exchange Act, as amended, and otherwise in accordance with applicable securities laws in any other jurisdiction.
About Orum’s TPD²® Approach
Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²®) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.
About Orum Therapeutics
Orum Therapeutics is a clinical-stage biotech pioneering the development of cell-specific, targeted protein degraders (TPD²®) with the precision of antibody targeting to improve cancer treatment for more patients. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum's novel targeted protein degrader payloads are designed to selectively degrade key intracellular proteins, offering a highly targeted approach to treating difficult-to-treat diseases. Orum is located in Lexington, MA, US, and Daejeon, South Korea. For more info, visit www.orumrx.com.
Orum Therapeutics Forward-Looking Statements
This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum. Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the commencement of trading in Orum’s shares, the anticipated gross proceeds of the offering, the closing of the offering, the potential therapeutic value of Orum’s technologies; and the potential for clinical success for ORM-5029 are forward-looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertainty of success in research and development activities; risks related to clinical trials, including potential delays, safety issues, or negative results; competition from alternative therapies; the risk that product candidates may not be successfully commercialized or adopted; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, health care reform, prices, and reimbursement rates. The forward-looking statements in this presentation speak only as of the date of this release, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release.
Contacts
Corporate: Kayla (Gyebang) Mo, Director, IR/PR, Orum Therapeutics, media@orumrx.com
Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., +1-858-344-8091, jessica@litldog.com
Notice of New Share Issuance for KOSDAQ Listing
The Board of Directors of Orum Therapeutics (the "Company") resolved on December 20, 2024, to issue new shares for the purpose of listing on the KOSDAQ market. In accordance with the Korean Commercial Code and the Company's Articles of Incorporation, we hereby announce the following:
1. Type and Number of New Shares: 2,500,000 registered common shares
Public Offering: 2,500,000 shares
2. Par Value: KRW 100 per share
3. Issue Price: To be determined in consultation with Korea Investment & Securities Co., Ltd., the lead underwriter for the Company's KOSDAQ listing, based on the book-building results and in accordance with Article 5 (Determination of Public Offering Price of Stocks, etc.) of the Regulations on Securities Underwriting Business.
4. Method of Subscription:
Shares will be allotted to third parties pursuant to Article 10, Paragraph 2, Item 8 of the Company's Articles of Incorporation.
The lead underwriter will be entrusted with the underwriting and public offering of the new shares.
The allocation of shares will be conducted in accordance with Article 9 (Stock Allocation) of the Regulations on Securities Underwriting Business.
5. Payment Date (Expected): February 7, 2025 (Friday)
6. Others: Other details are delegated to the Chief Executive Officer.
Orum Therapeutics
2F, 281-25 Munji-ro, Yuseong-gu, Daejeon, Republic of Korea
Sung Joo Lee,
Chief Executive Officer
Orum Therapeutics to Relaunch Initial Public Offering Next Year
Strategic decision reflecting market conditions
Orum Therapeutics (“Orum”) will resume its listing on the KOSDAQ market next year.
On November 29, Orum announced that it has postponed its initial public offering (IPO) plan that was scheduled for next month. The company had been preparing for the listing after submitting its securities registration statement.
“We have made the decision to postpone the public listing considering the current market situation, which is in the best interest of our stakeholders. We will continue to fulfill our mission of developing innovative drugs for patients in need,” said Sung Joo Lee, Ph.D., CEO of Orum Therapeutics.
About Orum Therapeutics
Orum Therapeutics is a private, clinical-stage biotech pioneering the development of the cell-specific, targeted protein degraders (TPD²) approach, which combines the precision of antibody targeting technology. Orum is located in Lexington, MA, US, and Daejeon, South Korea. For more info, please visit www.orumrx.com.